These pre-clinical data have encouraged clinical trials targeting PD-1 and PD-L1, either as monotherapy or in combination with radiation or chemotherapy, in pancreatic cancer (Table 1, current active clinical trials, and Table 2, past clinical trials targeting pancreatic cancer TME). Here, PDCD1 is linked to familial pancreatic carcinoma.